FDA Greenlights Updated COVID-19 Shots for Vulnerable Amid Rising Cases

The U.S. Food and Drug Administration (FDA) gave its nod on Thursday, August 27, 2026, to new, updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax-Sanofi. These shots are specifically for people at higher risk of getting very sick, like older adults and those with existing health problems. This decision comes as COVID-19 cases are starting to go up in many parts of the United States, with a new variant spreading more widely. These updated vaccines are designed to protect against the JN.1 lineage XFG subvariant, which was the main type of the virus going around last season. Pfizer-BioNTech 'Comirnaty XFG' and Moderna 'Spikevax' and 'mNEXSPIKE' are mRNA-based, while Novavax-Sanofi 'Nuvaxovid' uses a different, protein-based method. The Centers for Disease Control and Prevention (CDC) has recommended these vaccines based on individual choice, especially for those over 65 and at high risk, though its advisory committee faces legal hurdles which could affect how easily people get their shots in some places. With Pfizer and BioNTech already shipping their doses and Moderna coming soon, these vaccines should quickly become available in pharmacies and clinics. Public health experts are closely watching the spread of current strains like the dominant XFG.1.1 variant, noting that while infections are increasing, severe cases and hospitalizations are currently lower than previous summer surges. People with conditions like heart disease, diabetes, or obesity are urged to consider getting vaccinated to protect themselves as the virus continues to evolve.